ERINHA's concept
Pathogens We Study
Unique facilities and scientists
Twitter feeds
;
The @WHO released a guideline "#Ebola and #Marburg disease outbreaks: infection prevention and control research priorities in health care settings" that identified multiple research gaps in key areas that lacked strong evidence to help recommendations
https://www.who.int/publications/i/item/9789240098381
More filoviruses 🦠 are being discovered (see article in @Nature_NPJ). It is thus crucial to develop broadly active therapeutics 💊 that are active against a wide range of viruses, including newly emerging ones.
That's the purpose of the #NAVIPP project
https://www.nature.com/articles/s44298-024-00050-4
Learn about the #BSL4ZNET (BioSafety Level 4 Zoonotic laboratory NETwork) conference 🧬💻
https://erinha.eu/newsroom/bsl4znet-international-conference-2024/
A real-world study conducted in the Democratic Republic of the Congo (DRC) found that Merck's rVSV-ZEBOV #Ebola vaccine was 84% effective against infection during the country's 2018-2020 Ebola outbreak 🦠✅
https://www.cidrap.umn.edu/ebola/study-during-dr-congos-outbreak-finds-84-protection-ebola-vaccine
